Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 5 | Journal of Biomedical Science

Fig. 5

From: Gemcitabine resistance by CITED4 upregulation via the regulation of BIRC2 expression in pancreatic cancer

Fig. 5

BIRC2 mediates GEM-resistance features related to CITED4 in PC. A mRNA and B protein expression levels of BIRC2 in BIRC2-knockdown PANC-1 and L3.6pl-GR cells. β-Actin was used as an internal control for mRNA and protein expression. C Cell viability was measured using a CCK-8 assay. D Representative image of the colony-formation assay in PANC-1 and L3.6pl-GR (top) cells. Relative quantification of the colony number (bottom). E Representative image of the cell-migration assay (top). Relative quantification of the number of migrated cells (bottom). F Comparative analysis of apoptosis after GEM treatment of BIRC2-knockdown PANC-1 and L3.6pl-GR cells using flow cytometry. Fluorescence-activated cell sorting analysis of siNC- and siBIRC2-transfected cells treated with (1 µg/ml) or without GEM for 48 h, following which the cells were stained with Annexin V-FITC and propidium iodide (upper panel). Percentages of viable, early apoptotic, late apoptotic, and necrotic cells. G Caspase-3/7 activity was measured using Caspase-Glo 3/7 Assay kit. BIRC2-knockdown PANC-1 (upper) and L3.6pl-GR (bottom) cells were treated with 1 µg/ml GEM for 48 h. *P < 0.05 and ***P < 0.001

Back to article page

Journal of Biomedical Science

ISSN: 1423-0127